Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

499 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Curating Genetic Associations With Rheumatologic Autoimmune Diseases to Improve Patient Outcomes.
Bridges SL Jr, Shapira R, Aksentijevich I, Mack SJ, Merriman TR, Klein CJ, Bowen BM, Klein TE; ClinGen Rheumatologic Autoimmune Disease Clinical Domain Working Group. Bridges SL Jr, et al. Arthritis Rheumatol. 2024 Nov;76(11):1577-1581. doi: 10.1002/art.42943. Epub 2024 Aug 1. Arthritis Rheumatol. 2024. PMID: 38965695 Free article. No abstract available.
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian KC, Galateanu C, Bongardt S, Stach C, Beaudot C, Kilgallen B, Gordon C; EMBODY Investigator Group. Clowse ME, et al. Arthritis Rheumatol. 2017 Feb;69(2):362-375. doi: 10.1002/art.39856. Arthritis Rheumatol. 2017. PMID: 27598855 Free PMC article. Clinical Trial.
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group. van der Heijde D, et al. Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22. Lancet. 2018. PMID: 30360964 Clinical Trial.
Multimorbidity phenotypes in ankylosing spondylitis and their association with disease activity and functional impairment: Data from the prospective study of outcomes in ankylosing spondylitis cohort.
Karmacharya P, Crowson CS, Lennon RJ, Poudel D, Davis JM 3rd, Ogdie A, Liew JW, Ward MM, Ishimori M, Weisman MH, Brown MA, Rahbar MH, Hwang MC, Reveille JD, Gensler LS. Karmacharya P, et al. Among authors: reveille jd. Semin Arthritis Rheum. 2024 Feb;64:152282. doi: 10.1016/j.semarthrit.2023.152282. Epub 2023 Nov 7. Semin Arthritis Rheum. 2024. PMID: 37995469
499 results